AITRICS has secured a $24 million Series C funding round to accelerate development of its flagship AI-powered hospital software VitalCare (and upcoming clinician copilot V.Doc Pro), expand into new markets, and deepen its clinical-AI research pipeline.
Glimpse:
The fresh capital will be used to enhance VitalCare’s early-warning capabilities (predicting inpatient deterioration, sepsis, cardiac arrest etc.), build out new AI-assisted tools for clinicians, and support AITRICS’ expansion into new Asian and global markets including subsidiaries in Japan and planned entries into Vietnam and Hong Kong.
Founded in 2016, AITRICS is a South-Korea–based medical-AI company specialising in critical-care decision support. Its core product, VitalCare, analyses real-time electronic medical record (EMR) and vital-sign data to detect early signs of deterioration such as sepsis, sudden cardiac arrest, or organ failure allowing clinicians to intervene earlier. 2025, the company announced it had raised 35 billion won (≈ USD 24 million) in a Series C round, bringing total funding to ~USD 50 million. The round was led by existing investors (Premier Partners, Hanriver Partners, Mirae Asset Venture Investment, etc.), with new investors joining in.
According to AITRICS, the funds will be directed toward:
Enhancing VitalCare’s AI capabilities and expanding its clinical indications.
Developing a next-generation clinician-assist platform, V.Doc Pro, which will act as an AI “copilot” aiding doctors with decision support, documentation, or patient-data interpretation. Expanding geographic reach: AITRICS recently set up a subsidiary in Tokyo, and now plans to enter markets such as Vietnam and Hong Kong.
The company also announced that its information-security and data-governance posture has been reinforced obtaining ISO/IEC 27001 & 27701 certifications which could support broader global adoption and regulatory compliance.
“With this new funding, we are one step closer to making VitalCare and our AI-powered copilot solutions a standard of care ensuring every patient gets timely, data-driven monitoring, no matter where they are.”
By
HB Team
